Health

Women More Likely to Beat Cancer than Men, Research Shows

| by
article imagearticle image

Recent research shows that women are far more likely to survive cancer than men are, mostly because breast cancer is easier to beat than prostate.

Breast cancer is the most common cancer amongst women, while prostate is the most common cancer amongst men. 

Macmillan Cancer Support said around 260,000 women are still alive ten years after they are diagnosed with cancer, while 140,000 men are. 

They believe this is because 80 percent of the 50,000 women diagnosed with breast cancer each year can expect to live at least another ten years.

Popular Video

A police officer saw a young black couple drive by and pulled them over. What he did next left them stunned:

Popular Video

A police officer saw a young black couple drive by and pulled them over. What he did next left them stunned:

As for men, just 65 percent of the 41,000 who are diagnosed with prostate cancer each year are expected to live ten years or more.

On top of that, men are more likely to be diagnosed with lung cancer, which has only a 10 percent survival rate.

Each year, there are 23,000 new cases of cancer in men compared to 19,000 women. To make matters worse, men are less likely to go to a doctor when they feel ill, meaning they could allow cancer to spread by ignoring symptoms.

Ciaran Devane, of Macmillan Cancer Support, said, "Breast cancer is the big success story of cancer. Since the 1980s, the average survival rate has been above ten years. Lots of people get it, almost exclusively women, but they will live a long time."

"But if you compare that with the big male cancer, prostate, survival isn't as good."

Though cancer diagnoses seem to be rising, cancer survival rates have quadrupled in the past 40 years.

Doctors are now urging other practitioners to place importance on prostate cancer screening, as the All Parliamentary Group on Cancer said treatment for men was less prompt and they did not have as much support.

Breast cancer research also receives much more funding than prostate, with $1,082 and $553 received per case diagnosed, respectively. 

Sources: Daily Mail, CW15